Anoro Ellipta powder 22mkg + 55mkg / dose, 30 dose
Expiration Date: 05/2027
Russian Pharmacy name:
Аноро Эллипта порошок 22мкг+55мкг/доза, 30 доз
Supportive bronchodilator therapy aimed at relieving symptoms of chronic obstructive pulmonary disease.
Inhalation
Anoro ElliptaЃ should be used every day at the same time, once a day. The recommended dose of Anoro ElliptaЃ: one inhalation 22 + 55 mcg / dose 1 time per day. It was found that in some patients the use of Anoro ElliptaЃ at a dosage of 22 + 113 ?g / dose 1 time per day has an additional advantage in terms of the effect on pulmonary function and the frequency of emergency medications. The maximum dose is one inhalation of Anoro ElliptaЃ at a dosage of 22 + 113 ?g / dose 1 time per day.
Special patient groups
Children. This drug is not used for the treatment of patients under the age of 18, given the indications for its administration.
Elderly patients. Patients over 65 years of age do not need dose adjustment (see Pharmacokinetics).
Impaired renal function. No dose adjustment is required for patients with impaired renal function (see Pharmacokinetics).
Liver dysfunction. Patients with mild to moderate hepatic impairment do not require dose adjustment. Studies on the use of a combination of vilanterol and umeclidinium in patients with severe hepatic impairment have not been conducted (see 'Pharmacokinetics').
Recommendations for use
When using the ElliptЃ inhaler for the first time, there is no need to check its correct operation or special preparation of the inhaler for use. The recommendations for use indicated below should be followed consistently.
The ElliptaЃ inhaler is packaged in a container containing a desiccant silica gel sachet that is not intended to be eaten or inhaled. This bag should be disposed of. After removing the inhaler from the container, its lid is in the closed position. Do not open it until ready to take the drug.
Instructions for using the inhaler ElliptЃ
When opening and closing the lid of the ElliptЃ inhaler without taking the drug, one dose is lost. This dose remains closed inside the inhaler, but it will not be available to receive. It is impossible to accidentally receive a large dose or a double dose in one inhalation.
One dose of medication is ready for inhalation after each opening of the lid.
The dose counter shows how many doses of the drug are left in the inhaler. Before using the inhaler, the dose counter shows the number 30. Each time you open the lid, the number of doses decreases by 1. When there are less than 10 doses remaining, half of the counter turns red. After the last dose of the drug has been consumed, half of the counter is highlighted in red, the counter shows the number 0. This means that the inhaler is empty. When you open the lid after that, the dose counter will turn completely red.
Dose preparation
Do not open the lid until you are ready to take the drug. Do not shake the inhaler.
1. Push the cover down until it clicks.
2. The dose of the drug is ready for inhalation, and in confirmation of this, the counter decreases the number of doses by one.
3. If the counter has not decreased the number of doses after clicking, then the inhaler is not ready to deliver a dose of the drug. In this case, you should contact by phone or the address specified in the subsection 'For additional information, contact'.
4. Do not shake the inhaler.
Inhalation of the drug
1. Holding the inhaler at some distance from the mouth, exhale as deep as possible. Do not breathe out into the inhaler.
2. Place the mouthpiece between your lips and wrap your lips tightly around it. Do not cover the ventilation hole with your fingers.
The lips should closely follow the shape of the inhaler mouthpiece.
3. Take one deep, long, even breath. Hold your breath as much as possible (at least 3-4 s).
4. Remove the inhaler from your mouth.
5. Exhale slowly and calmly.
If the inhaler is used correctly, the patient may not taste or feel the drug coming in.
Closing the inhaler
If necessary, clean the mouthpiece, use a dry paper towel before closing the lid.
Raise the lid until it stops, achieving complete closure of the mouthpiece.
| Dosed powder for inhalation, 22 + 55 mcg / dose | 1 dose / cell * |
| Vilanterol strip | |
| active substance: | |
| vilanterol triphenatate micronized | 40 mcg |
| (equivalent to 25 mcg ** vilanterol) | |
| excipients: magnesium stearate - 125 mcg; lactose monohydrate - up to 12.5 mg | |
| Umeclidinium strip | |
| active substance: | |
| umeclidinium bromide micronized | 74.2 mcg |
| (equivalent to 62.5 mcg ** umeclidinium) | |
| excipients: magnesium stearate - 75 mcg; lactose monohydrate - up to 12.5 mg |
| Dosed powder for inhalation, 22 + 113 mcg / dose | 1 dose / cell * |
| Vilanterol strip | |
| active substance: | |
| vilanterol triphenatate micronized | 40 mcg |
| (equivalent to 25 mcg ** vilanterol) | |
| excipients: magnesium stearate - 125 mcg; lactose monohydrate - up to 12.5 mg | |
| Umeclidinium strip | |
| active substance: | |
| umeclidinium bromide micronized | 148.3 mcg |
| (equivalent to 125 mcg ** umeclidinium) | |
| excipients: magnesium stearate - 75 mcg; lactose monohydrate - up to 12.5 mg | |
| * To compensate for losses during filling the cells during the production of the finished product, a mixture of vilanterol and excipients can be added to the finished product with an excess of up to 8%, a mixture of umeclidinium and excipients - with an excess of up to 6%. | |
| ** The nominal amount of active ingredient is indicated, the delivered amount of vilanterol is 22 ?g, umeclidinium - 55 and 113 ?g, which corresponds to the indicated dosages. |
a history of severe allergic reactions to milk protein or hypersensitivity to active ingredients or any other component of the drug;
children under 18 years old.
With care: after using sympathomimetics and muscarinic receptor antagonists, incl. and Anoro ElliptaЃ, from the CCC side, such undesirable reactions as arrhythmia (for example, atrial fibrillation and tachycardia) can be observed. In this regard, patients with severe forms of cardiovascular diseases should be prescribed Anoro ElliptaЃ with caution. Given the antimuscarinic activity of this drug, it should be used with caution in patients with angle-closure glaucoma or urinary retention.